Please wait while the transcript is being prepared...
0:00
It gives me great
pleasure to talk
to you about
polymyalgia rheumatica,
the causes of PMR symptoms,
the diagnosis,
treatment, and the
outlook of the condition.
0:18
Here are my disclosures.
0:21
This is the evidence
base for the talk.
Primarily, it includes
the BSR guidelines
on PMR published back in 2010.
The 2012 EULAR ACR
classification criteria
for PMR, published in 2012.
The patient-reported
outcomes in PMR.
The clinical outcomes,
quality of life
and diagnostic
uncertainty in PMR.
The PMR UK outcome study,
which was completed
back in 2006.
And of course the 2015 EULAR
ACR PMR recommendations.
I shall also cite
recent papers about
the pathophysiology
of PMR based
on the work that has come out
of Groningen in the Netherlands.
1:16
The areas that will be covered
in my talk: one, the
pathophysiology,
two, the approach
that we take to PMR
as well as the
polymyalgic syndrome.
We will talk in detail
about the 2015 EULAR ACR
and 2009 BSR recommendations.
We'll talk about the
overarching principles,
indications for early
specialist referral,
the role of disability and
quality of life in PMR.
How do we assess PMR?
How do we treat PMR
with glucocorticoids,
initial dosage and
glucocorticoid taper?
Whether there's a role for
disease-modifying agents
such as methotrexate,
leflunomide,
and the increasing scope
of biologics in PMR.
The role of lifestyle measures
such as exercise and, of course,
we will talk a little bit about
some of the clinical
trials that are going on.
